Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (361-370 of 477) with videos related to

Pageof 48
Sort By:
Annals of the Rheumatic Diseases|April 7, 2007
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite studyDaniel E Furst, Norman Gaylis, Vance Bray, et al.
Annals of the Rheumatic Diseases|January 18, 2023
Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantationBurcu Ayoglu, Michele Donato, Daniel E Furst, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 3, 2024
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm TrialGeorge E Georges, Dinesh Khanna, Mark H Wener, et al.
Annals of the Rheumatic Diseases|November 10, 2018
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohortsElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
Clinical Immunology (Orlando, Fla.)|October 28, 2004
Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)Jan Storek, Zhao Zhao, Eugene Lin, et al.
Annals of the Rheumatic Diseases|May 9, 2007
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisPhilip J Clements, Michael D Roth, Robert Elashoff, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 1, 2020
Large-Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung FibrosisChiara Bellocchi, Jun Ying, Ellen A Goldmuntz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 14, 2023
A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Christopher P Denton, Daniel E Furst, et al.
Rheumatology (Oxford, England)|April 22, 2017
Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort StudyLinda Kwakkenbos, Brett D Thombs, Dinesh Khanna, et al.
Seminars in Arthritis and Rheumatism|April 25, 2026
Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT studyDorthe B Berthelsen, Tobias Haugegaard, Mohammed M Kamso, et al.
Pageof 48

Showing results (361-370 of 477) with videos related to

Sort By:
Pageof 48
Annals of the Rheumatic Diseases|April 7, 2007
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite studyDaniel E Furst, Norman Gaylis, Vance Bray, et al.
Annals of the Rheumatic Diseases|January 18, 2023
Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantationBurcu Ayoglu, Michele Donato, Daniel E Furst, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 3, 2024
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm TrialGeorge E Georges, Dinesh Khanna, Mark H Wener, et al.
Annals of the Rheumatic Diseases|November 10, 2018
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohortsElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
Clinical Immunology (Orlando, Fla.)|October 28, 2004
Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)Jan Storek, Zhao Zhao, Eugene Lin, et al.
Annals of the Rheumatic Diseases|May 9, 2007
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisPhilip J Clements, Michael D Roth, Robert Elashoff, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 1, 2020
Large-Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung FibrosisChiara Bellocchi, Jun Ying, Ellen A Goldmuntz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 14, 2023
A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Christopher P Denton, Daniel E Furst, et al.
Rheumatology (Oxford, England)|April 22, 2017
Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort StudyLinda Kwakkenbos, Brett D Thombs, Dinesh Khanna, et al.
Seminars in Arthritis and Rheumatism|April 25, 2026
Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT studyDorthe B Berthelsen, Tobias Haugegaard, Mohammed M Kamso, et al.
Pageof 48